LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 56

Search options

  1. Article ; Online: Survival of Women Previously Diagnosed of Melanoma with Subsequent Pregnancy

    Nieves Martínez-Campayo / Sabela Paradela de la Morena / Sonia Pértega-Díaz / Luisa Iglesias Pena / Pia Vihinen / Kalle Mattila / Marko B. Lens / Antonio Tejera-Vaquerizo / Eduardo Fonseca

    Journal of Clinical Medicine, Vol 11, Iss 83, p

    A Systematic Review and Meta-Analysis and a Single-Center Experience

    2022  Volume 83

    Abstract: Melanoma incidence has increased over the last few decades. How the prognosis of a previously diagnosed melanoma may be affected by a woman’s subsequent pregnancy has been debated in the literature since the 1950s, and the outcomes are essential to women ...

    Abstract Melanoma incidence has increased over the last few decades. How the prognosis of a previously diagnosed melanoma may be affected by a woman’s subsequent pregnancy has been debated in the literature since the 1950s, and the outcomes are essential to women who are melanoma survivors in their childbearing years. The main objective of this systematic review is to improve the understanding of whether the course of melanoma in a woman may be altered by a subsequent pregnancy and to help clinicians’ diagnosis. Eligible studies for the systematic review were clinical trials, observational cohort studies and case-control studies that compared prognosis outcomes for non-pregnant patients with melanoma, or pregnant before melanoma diagnosis, versus pregnant patients after a diagnosis of melanoma. The search strategy yielded 1101 articles, of which 4 met the inclusion criteria for the systematic review. All the studies were retrospective non-randomised cohorts with patients with melanomas diagnosed before pregnancy. According to our findings, a subsequent pregnancy was not a significant influence on the outcome of a previous melanoma. However, given the small number of identified studies and the heterogeneous data included, it is recommended to approach these patients with caution, and counselling should be given by known prognostic factors. We also reviewed the medical records of 84 patients of childbearing age (35.8 ± 6.3 years, range 21–45 years) who were diagnosed with cutaneous invasive melanoma in our hospital between 2008 and 2018 (N = 724). Of these, 11 (13.1%) had a pregnancy after melanoma diagnosis (age at pregnancy: 35.6 ± 6.3 years). No statistical differences in outcome were detected.
    Keywords melanoma ; pregnancy ; prognosis ; meta-analysis ; systematic review ; survival ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2022-12-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article: The role of biological response modifiers in malignant melanoma.

    Lens, Marko B

    Expert opinion on biological therapy

    2004  Volume 3, Issue 8, Page(s) 1225–1231

    Abstract: This article reviews the existing data in an attempt to address the role of biological response modifiers (IFN-alpha and IL-2) in the management of melanoma. Eight prospective controlled Phase III trials evaluating IFN-alpha therapy are discussed. As the ...

    Abstract This article reviews the existing data in an attempt to address the role of biological response modifiers (IFN-alpha and IL-2) in the management of melanoma. Eight prospective controlled Phase III trials evaluating IFN-alpha therapy are discussed. As the results from these trials have been heterogeneous and inconsistent, the role of IFN-alpha in the adjuvant treatment of stage II and III melanoma patients remains to be defined. IL-2 possesses modest antitumour activity in melanoma yielding objective response in approximately 15% of patients. Many toxic effects are induced by high-dose IL-2 therapy. Combinations of chemotherapy and biological response modifiers and their impact on tumour response and survival are discussed.
    MeSH term(s) Clinical Trials as Topic ; Humans ; Immunologic Factors/therapeutic use ; Interferon-alpha/therapeutic use ; Interferons/metabolism ; Interleukin-2/metabolism ; Melanoma/therapy ; Randomized Controlled Trials as Topic ; Skin Neoplasms/therapy ; Time Factors
    Chemical Substances Immunologic Factors ; Interferon-alpha ; Interleukin-2 ; Interferons (9008-11-1)
    Language English
    Publishing date 2004-03-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2052501-1
    ISSN 1471-2598
    ISSN 1471-2598
    DOI 10.1517/14712598.3.8.1225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Survival of Women Previously Diagnosed of Melanoma with Subsequent Pregnancy: A Systematic Review and Meta-Analysis and a Single-Center Experience.

    Martínez-Campayo, Nieves / Paradela de la Morena, Sabela / Pértega-Díaz, Sonia / Iglesias Pena, Luisa / Vihinen, Pia / Mattila, Kalle / Lens, Marko B / Tejera-Vaquerizo, Antonio / Fonseca, Eduardo

    Journal of clinical medicine

    2021  Volume 11, Issue 1

    Abstract: Melanoma incidence has increased over the last few decades. How the prognosis of a previously diagnosed melanoma may be affected by a woman's subsequent pregnancy has been debated in the literature since the 1950s, and the outcomes are essential to women ...

    Abstract Melanoma incidence has increased over the last few decades. How the prognosis of a previously diagnosed melanoma may be affected by a woman's subsequent pregnancy has been debated in the literature since the 1950s, and the outcomes are essential to women who are melanoma survivors in their childbearing years. The main objective of this systematic review is to improve the understanding of whether the course of melanoma in a woman may be altered by a subsequent pregnancy and to help clinicians' diagnosis. Eligible studies for the systematic review were clinical trials, observational cohort studies and case-control studies that compared prognosis outcomes for non-pregnant patients with melanoma, or pregnant before melanoma diagnosis, versus pregnant patients after a diagnosis of melanoma. The search strategy yielded 1101 articles, of which 4 met the inclusion criteria for the systematic review. All the studies were retrospective non-randomised cohorts with patients with melanomas diagnosed before pregnancy. According to our findings, a subsequent pregnancy was not a significant influence on the outcome of a previous melanoma. However, given the small number of identified studies and the heterogeneous data included, it is recommended to approach these patients with caution, and counselling should be given by known prognostic factors. We also reviewed the medical records of 84 patients of childbearing age (35.8 ± 6.3 years, range 21-45 years) who were diagnosed with cutaneous invasive melanoma in our hospital between 2008 and 2018 (N = 724). Of these, 11 (13.1%) had a pregnancy after melanoma diagnosis (age at pregnancy: 35.6 ± 6.3 years). No statistical differences in outcome were detected.
    Language English
    Publishing date 2021-12-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11010083
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.

    Ferrucci, Pier Francesco / Lens, Marko / Cocorocchio, Emilia

    Current oncology reports

    2021  Volume 23, Issue 12, Page(s) 138

    Abstract: Purpose of review: To review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with BRAF-mutated metastatic melanoma.: Recent findings: Programmed death-1 pathway inhibitors ... ...

    Abstract Purpose of review: To review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with BRAF-mutated metastatic melanoma.
    Recent findings: Programmed death-1 pathway inhibitors administered with BRAF/MEK inhibitors showed promising anti-tumour activity in BRAF-mutated advanced melanoma and were investigated for safety and efficacy in three large international clinical trials. Although, in two out of those three randomized phase III studies, progression-free survival (PFS) did not reach statistical significance, results showed that duration of response (DOR) and overall survival (OS) were improved using combined therapy, sustaining the scientific rationale for its use at least in a subset of metastatic melanomas. However, the frequent occurrence of autoimmunity-induced toxicities should be considered since it is limiting the continuity and the wide application of these regimens. Novel treatment modalities combining targeted therapy with checkpoint inhibitors require further clinical investigation and elucidation of their effect on the immune system and cancer cell modulation.
    MeSH term(s) Cell Proliferation/drug effects ; Humans ; Immunologic Factors/therapeutic use ; Melanoma/drug therapy ; Melanoma/immunology ; Molecular Targeted Therapy/methods ; Mutation/drug effects ; Proto-Oncogene Proteins B-raf/therapeutic use ; Skin Neoplasms/drug therapy
    Chemical Substances Immunologic Factors ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2021-11-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057359-5
    ISSN 1534-6269 ; 1523-3790
    ISSN (online) 1534-6269
    ISSN 1523-3790
    DOI 10.1007/s11912-021-01134-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Anterior tab flap versus standard underlay myringoplasty in children.

    D'Eredità, Riccardo / Lens, Marko B

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

    2009  Volume 30, Issue 6, Page(s) 777–781

    Abstract: Objectives: Tympanic membrane (TM) perforation closure can present a problem in children, especially in anterior and total perforations, because of the anterior's lack of support for the graft. It was suggested that the anterior tab flap (ATF) ... ...

    Abstract Objectives: Tympanic membrane (TM) perforation closure can present a problem in children, especially in anterior and total perforations, because of the anterior's lack of support for the graft. It was suggested that the anterior tab flap (ATF) myringoplasty, an underlay graft with an anterior tab under the TM annulus, could provide better stability of the graft. We undertook a prospective, randomized, controlled study to compare the ATF myringoplasty with the standard underlay (SU) myringoplasty in children.
    Methods: We randomly assigned 59 children to undergo ATF myringoplasty and 52 to undergo SU myringoplasty at a tertiary care pediatric institution. Surgery was performed under general anesthesia in all patients. The primary outcome was the healing of the TM; the secondary outcomes were anterior blunting of the graft and presence of retraction of the TM. Two years of follow-up were obtained in all enrolled children.
    Results: At 2 years of follow-up, there were 55 stable TM closures in the ATF arm and 44 in the SU arm. Although the TM closure was higher in the ATF arm than in the SU arm (93.2 and 84.6%, respectively), the results were not statistically significant (odds ratio = 0.4, 95% confidence interval = 0.12-1.41). Anterior blunting and TM retraction were not encountered.
    Conclusion: The ATF myringoplasty is a safe and effective method for TM closure in children. However, compared with the SU myringoplasty, the ATF myringoplasty is not associated with an overall decrease in the incidence of the residual perforations. Further assessment in a larger study is proposed.
    MeSH term(s) Adolescent ; Anesthesia, General ; Child ; Child, Preschool ; Confidence Intervals ; Endoscopy ; Female ; Follow-Up Studies ; Humans ; Male ; Myringoplasty/methods ; Odds Ratio ; Prospective Studies ; Treatment Outcome ; Tympanic Membrane/anatomy & histology ; Tympanic Membrane/surgery
    Language English
    Publishing date 2009-09
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 2036790-9
    ISSN 1537-4505 ; 1531-7129
    ISSN (online) 1537-4505
    ISSN 1531-7129
    DOI 10.1097/MAO.0b013e3181b285d4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Contact-diode laser repair of bony choanal atresia: a preliminary report.

    D'Eredità, Riccardo / Lens, Marko B

    International journal of pediatric otorhinolaryngology

    2008  Volume 72, Issue 5, Page(s) 625–628

    Abstract: Objectives: To demonstrate the use of the contact-diode laser (CDL) at 810 nm wavelength for the transnasal endoscopic repair of bilateral bony choanal (BBCA) in low-weight newborns.: Methods: Prospective study at a tertiary-care pediatric ... ...

    Abstract Objectives: To demonstrate the use of the contact-diode laser (CDL) at 810 nm wavelength for the transnasal endoscopic repair of bilateral bony choanal (BBCA) in low-weight newborns.
    Methods: Prospective study at a tertiary-care pediatric institution of four neonates with BBCA aged 3-5 days, weighing on average 2.34 kg. BBCA was opened by transnasal delivery of CDL through a 600 microm diameter glass fiber. Children were stented post-operatively, and revision surgery performed when needed.
    Results: All children were successfully treated for BBCA with CDL. Two children needed only one surgery, one child needed two surgeries, and one patient required three procedures, in order to establish patient choanae at last follow-up ranging from 16 to 30 months.
    Conclusion: We found the fiber-delivered contact-diode laser to permit correction of BBCA in four low-birth weight neonates. To the best of our knowledge, this report is the first to demonstrate the successful use of CDL for the management of BBCA.
    MeSH term(s) Choanal Atresia/diagnosis ; Choanal Atresia/surgery ; Endoscopy ; Humans ; Infant, Newborn ; Laser Therapy ; Reoperation ; Stents ; Tomography, X-Ray Computed
    Language English
    Publishing date 2008-05
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 754501-0
    ISSN 1872-8464 ; 0165-5876
    ISSN (online) 1872-8464
    ISSN 0165-5876
    DOI 10.1016/j.ijporl.2008.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials.

    Lens, Marko B / Dawes, Martin

    The Lancet. Oncology

    2003  Volume 4, Issue 6, Page(s) 359–364

    Abstract: Isolated limb perfusion is a surgical procedure for delivering a high dose of chemotherapeutic or immunochemotherapeutic agent to a localised area, thus avoiding the severity of side-effects caused by systemic administration. This technique is generally ... ...

    Abstract Isolated limb perfusion is a surgical procedure for delivering a high dose of chemotherapeutic or immunochemotherapeutic agent to a localised area, thus avoiding the severity of side-effects caused by systemic administration. This technique is generally used for treatment of patients with tumours of the limbs and extremities. We have done a systematic review of randomised controlled trials assessing the effectiveness of this treatment in patients with melanoma of the extremities. Four trials of 1038 patients met our inclusion criteria and were analysed. Although our analysis confirmed the reported increase in survival in two of the trials, neither had sufficient power to detect significant benefit for perfusion. Results from the trials showed that prophylactic perfusion has an equivocal effect on survival in patients with limb melanoma. Therefore, current evidence suggests that prophylactic isolated limb perfusion cannot be recommended as a routine adjunct to standard surgery in patients with high-risk primary limb melanoma, but only as a treatment for local disease control if other forms of locoregional therapy are not available.
    MeSH term(s) Antineoplastic Agents, Alkylating/administration & dosage ; Chemotherapy, Cancer, Regional Perfusion ; Extremities ; Humans ; Melanoma/drug therapy ; Melphalan/administration & dosage ; Randomized Controlled Trials as Topic ; Survival Analysis
    Chemical Substances Antineoplastic Agents, Alkylating ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 2003-04-08
    Publishing country England
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/s1470-2045(03)01117-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Systemic chemotherapy in the treatment of malignant melanoma.

    Lens, Marko B / Eisen, Tim G

    Expert opinion on pharmacotherapy

    2003  Volume 4, Issue 12, Page(s) 2205–2211

    Abstract: Different postsurgical therapies are used for the treatment of metastatic melanoma. This article reviews the use of chemotherapeutic agents in the treatment of patients with metastatic malignant melanoma. A variety of single chemotherapy agents have been ...

    Abstract Different postsurgical therapies are used for the treatment of metastatic melanoma. This article reviews the use of chemotherapeutic agents in the treatment of patients with metastatic malignant melanoma. A variety of single chemotherapy agents have been evaluated, although the most widely used chemotherapeutic in the treatment of metastatic melanoma is dacarbazine. In order to improve the rate and duration of responses, combination chemotherapy was developed. The most common combined chemotherapy regimens used as standard for the treatment of metastatic melanoma are Dartmouth regimen, CVD (cisplatin + vinblastine + dacarbazine) and BOLD (bleomycin + vincristine + lomustine + dacarbazine). However, Phase III trials have failed to demonstrate a significant benefit in survival in patients treated with polychemotherapy compared to those treated with dacarbazine alone. The use of classical systemic chemotherapy still has a role in the treatment of patients with metastatic melanoma. Immunotherapy and biochemotherapy have no additional advantage over chemotherapy.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/therapeutic use ; Carmustine/therapeutic use ; Cisplatin/therapeutic use ; Clinical Trials as Topic ; Cyclophosphamide/therapeutic use ; Dacarbazine/therapeutic use ; Humans ; Lomustine/therapeutic use ; Melanoma/drug therapy ; Melanoma/mortality ; Melanoma/secondary ; Neoplasm Metastasis ; Skin Neoplasms/drug therapy ; Skin Neoplasms/mortality ; Skin Neoplasms/secondary ; Tamoxifen/therapeutic use ; Treatment Outcome ; Vincristine/therapeutic use
    Chemical Substances Tamoxifen (094ZI81Y45) ; Bleomycin (11056-06-7) ; Vincristine (5J49Q6B70F) ; Lomustine (7BRF0Z81KG) ; Dacarbazine (7GR28W0FJI) ; Cyclophosphamide (8N3DW7272P) ; Cisplatin (Q20Q21Q62J) ; Carmustine (U68WG3173Y)
    Language English
    Publishing date 2003-08-15
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1465-6566
    ISSN 1465-6566
    DOI 10.1517/14656566.4.12.2205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.

    Lens, Marko B / Dawes, Martin

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2003  Volume 20, Issue 7, Page(s) 1818–1825

    Abstract: Purpose: No standard systemic adjuvant therapy has been proven to increase overall survival in melanoma patients. The effect of interferon alfa (IFNalpha) as a single agent or in combination has been widely explored in clinical trials. The purpose of ... ...

    Abstract Purpose: No standard systemic adjuvant therapy has been proven to increase overall survival in melanoma patients. The effect of interferon alfa (IFNalpha) as a single agent or in combination has been widely explored in clinical trials. The purpose of this study was to assess the benefit of IFNalpha therapy in malignant melanoma.
    Methods: We performed a systematic review of randomized controlled trials comparing regimens with or without IFNalpha adjuvant therapy in melanoma patients. We assessed the effect of IFNalpha therapy on overall survival (OS), disease-free survival (DFS), melanoma recurrences, and toxicity. The quality of each trial was systematically evaluated.
    Results: Nine randomized controlled trials (RCTs) of IFNalpha therapy in melanoma patients were identified. Eight were published and one was unpublished. Eight trials comprising 3,178 patients fulfilled our inclusion criteria and were analyzed. Quality assessment scores ranged from 22 to 71, with a mean score of 55.4 (95% confidence interval, 53.8 to 57.0). For OS, only one trial reported a statistically significant benefit for IFNalpha, but our analysis did not confirm it. Two trials reported statistically significant benefit in DFS for the patients treated with IFNalpha, but our analysis confirmed it in only one trial. There was a wide clinical heterogeneity between included trials, making meta-analysis inappropriate.
    Conclusion: In our review, results from included RCTs demonstrated no clear benefit of IFNalpha therapy on OS in melanoma patients. A large RCT is required to answer whether a full regimen of IFNalpha therapy is effective and to identify the subgroups of patients who might benefit from IFNalpha treatment.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Disease-Free Survival ; Humans ; Interferon-alpha/adverse effects ; Interferon-alpha/therapeutic use ; MEDLINE ; Melanoma/drug therapy ; Neoplasm Recurrence, Local ; Randomized Controlled Trials as Topic ; Skin Neoplasms/drug therapy ; Survival Analysis ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Interferon-alpha
    Language English
    Publishing date 2003-02-05
    Publishing country United States
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2002.07.070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Economic evaluation in evidence-based practice.

    Lens, Marko B / Dawes, Martin

    Expert opinion on pharmacotherapy

    2002  Volume 3, Issue 9, Page(s) 1239–1243

    Abstract: The economic evaluation of health care interventions and technologies is an essential part of any modern healthcare system. In recent years a growing demand for information about the economic benefits of healthcare technologies has seen a significant ... ...

    Abstract The economic evaluation of health care interventions and technologies is an essential part of any modern healthcare system. In recent years a growing demand for information about the economic benefits of healthcare technologies has seen a significant increase in the number of published economic evaluations of healthcare. Economic evaluation reviews have demonstrated considerable methodological flaws in a significant number of analyses in health care. Widely accepted guidance regarding the manner in which multinational economic evaluations should be designed, analysed and presented is still awaited. The main types of economic analyses are described in this article, providing a framework along which to evaluate them.
    MeSH term(s) Costs and Cost Analysis/economics ; Costs and Cost Analysis/methods ; Evidence-Based Medicine/economics
    Language English
    Publishing date 2002-07-10
    Publishing country England
    Document type Evaluation Studies ; Lecture
    ZDB-ID 2001535-5
    ISSN 1465-6566
    ISSN 1465-6566
    DOI 10.1517/14656566.3.9.1239
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top